To further validate our finding that MNA+ cancers may deploy a GREB1-dependent mechanism to drive expression of pro-oncogenic genes such as MYO1B, independently of MYCN, we investigated medulloblastoma (MB), a childhood brain tumor that also harbors recurrent MNA (56–58). The gene discussed is MYCN; the disease is medulloblastoma.